Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?
Faron ESMO 2025

Af Inderes
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.